BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 24633661)

  • 61. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
    Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
    Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Schmitz N; Truemper L; Bouabdallah K; Ziepert M; Leclerc M; Cartron G; Jaccard A; Reimer P; Wagner E; Wilhelm M; Sanhes L; Lamy T; de Leval L; Rosenwald A; Roussel M; Kroschinsky F; Lindemann W; Dreger P; Viardot A; Milpied N; Gisselbrecht C; Wulf G; Gyan E; Gaulard P; Bay JO; Glass B; Poeschel V; Damaj G; Sibon D; Delmer A; Bilger K; Banos A; Haenel M; Dreyling M; Metzner B; Keller U; Braulke F; Friedrichs B; Nickelsen M; Altmann B; Tournilhac O
    Blood; 2021 May; 137(19):2646-2656. PubMed ID: 33512419
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.
    Hill BT; Rybicki L; Bolwell BJ; Smith S; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E; Sweetenham J
    Br J Haematol; 2011 Mar; 152(5):561-9. PubMed ID: 21223255
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
    Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Niederwieser D; Dölken G
    Ann Hematol; 2014 Sep; 93(9):1587-97. PubMed ID: 24782119
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
    Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
    Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
    Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
    Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
    Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
    Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
    Elstrom RL; Martin P; Ostrow K; Barrientos J; Chadburn A; Furman R; Ruan J; Shore T; Schuster M; Cerchietti L; Melnick A; Coleman M; Leonard JP
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):192-6. PubMed ID: 20511164
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
    Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.